Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed

Sakamori,Yuichi; Kim,Young  Hak; Yoshida,Hironori; Nakaoku,Takashi; Nagai,Hiroki; Yagi,Yoshitaka; Ozasa,Hiroaki; Mishima,Michiaki

doi:10.3892/mco.2014.452

Effect of liver toxicity on clinical outcome of patients with non‑small‑cell lung cancer treated with pemetrexed

Authors:
- Yuichi Sakamori
- Young Hak Kim
- Hironori Yoshida
- Takashi Nakaoku
- Hiroki Nagai
- Yoshitaka Yagi
- Hiroaki Ozasa
- Michiaki Mishima
View Affiliations

Affiliations: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kansai 606-8507, Japan
Published online on: November 4, 2014 https://doi.org/10.3892/mco.2014.452
Pages: 334-340

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver toxicity (LT) is a common side effect of pemetrexed (PEM); however, the effect of LT on clinical outcome has not been investigated in patients with non‑small‑cell lung cancer (NSCLC) treated with PEM. Between June, 2009 and June, 2012, a total of 95 chemo‑naive NSCLC patients received a PEM‑containing regimen in our hospital. We reviewed the medical records of those 95 patients and evaluated the incidence of LT. Furthermore, we investigated the association between LT and clinical outcome. In this analysis, LT was defined as any grade of aspartate aminotransferase or alanine aminotransferase elevation. A total of 67 patients (70.5%) developed LT, which occurred mostly during the first treatment cycle. Among these, 10 patients (10.5%) required a delay in treatment or a dose reduction from the subsequent cycle and PEM discontinuation was required in 1 patient. The response rate (RR) was 43.3 and 21.4% in patients with and in those without LT, respectively (P=0.0387). The median progression‑free survival (PFS) and overall survival (OS) were 6.3 and 24.2 months in patients with LT and 2.9 and 18.3 months in patients without LT, respectively (P<0.0001 for PFS and P=0.2426 for OS). The multivariate analysis demonstrated that LT exerted a significant positive effect on PFS (hazard ratio = 0.341; P<0.0001). In conclusion, LT was frequently observed in NSCLC patients treated with PEM; however, it was generally easily manageable. The improvement in RR and PFS observed in patients with LT suggested that LT may be a useful predictor of a favorable outcome in this patient population.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Schultz RM, Patel VF, Worzalla JF and Shih C: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res. 19:437–443. 1999.PubMed/NCBI
3	Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:1116–1123. 1997.PubMed/NCBI
4	Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 14:253–263. 2009. View Article : Google Scholar : PubMed/NCBI
5	Scagliotti G, Brodowicz T, Shepherd FA, et al: Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 6:64–70. 2011.PubMed/NCBI
6	Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ and Ackland SP: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol. 13:737–741. 2002. View Article : Google Scholar : PubMed/NCBI
7	Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J and Krejcy K: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 11:435–440. 2000. View Article : Google Scholar : PubMed/NCBI
8	Ohe Y, Ichinose Y, Nakagawa K, et al: Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res. 14:4206–4212. 2008. View Article : Google Scholar : PubMed/NCBI
9	Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S and Postmus PE: ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol. 14:455–460. 2003. View Article : Google Scholar : PubMed/NCBI
10	Goldstraw P, Crowley J, Chansky K, et al International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
11	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
12	Schneider E and Ryan TJ: Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 374:25–32. 2006. View Article : Google Scholar : PubMed/NCBI
13	McDonald AC, Vasey PA, Adams L, et al: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 4:605–610. 1998.PubMed/NCBI
14	Mita AC, Sweeney CJ, Baker SD, et al: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 24:552–562. 2006. View Article : Google Scholar : PubMed/NCBI
15	Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N and Groen HJ: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 27:2038–2045. 2009. View Article : Google Scholar : PubMed/NCBI
16	Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y and Kamatani N: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 12:183–190. 2002. View Article : Google Scholar : PubMed/NCBI
17	Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H and Kamatani N: Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics. 17:383–390. 2007. View Article : Google Scholar : PubMed/NCBI